Data updated: Mar 10, 2026
DEXILANT SOLUTAB
DEXLANSOPRAZOLE
Approved 2016-01-26
2
Indications
--
Phase 3 Trials
10
Years on Market
Details
- Status
- Discontinued
- First Approved
- 2016-01-26
- Routes
- ORAL
- Dosage Forms
- TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
DEXILANT SOLUTAB Approval History
Loading approval history...
What DEXILANT SOLUTAB Treats
2 FDA approvalsOriginally approved for its first indication in 2016 . Covers 2 distinct patient populations.
- Other (2)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
DEXILANT SOLUTAB FDA Label Details
ProDEXILANT SOLUTAB Patents & Exclusivity
Latest Patent: Mar 2029
Patents (7 active)
US9241910
Expires Mar 10, 2029
US8871273*PED
Expires Jul 11, 2028
US8871273
Expires Jan 11, 2028
US8461187*PED
Expires Jul 17, 2026
US9011926
Expires Feb 24, 2026
US9238029
Expires Jan 17, 2026
US8461187
Expires Jan 17, 2026
Source: FDA Orange Book
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.